Tauopathies are defined by progressive accumulation of tau amyloids. These assemble 30 around a protein seed, whose structure is unknown, but might explain the initiation of 31 pathology. We have purified and characterized distinct forms of tau monomer-either seed-32 competent or inert. Recombinant tau that was seed-competent triggered intracellular tau 33 aggregation, induced full length tau fibrillization in vitro, and exhibited intrinsic properties of 34 self-assembly. Tau monomer from AD brain, but not from controls, similarly seeded 35 aggregation, and self-assembled in vitro to form higher order, seed-competent structures. We 36 used crosslinking with mass spectrometry to identify distinct conformers of both recombinant 37 tau and human brain-derived protein. Theoretical models informed by this data suggest that 38 VQIINK and VQIVYK sequences, which support amyloid formation, are uniquely exposed in 39 all seed-competent structures. Our data imply that initiation of pathological aggregation 40 begins with conversion of tau monomer from an inert to a seed-competent form. 41 42 peer-reviewed)